Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease worldwide, with abnormal lipid accumulation in hepatocytes as its principal pathological alteration. Disruption of hepatic lipid homeostasis is associated with processes such as fatty acid uptake, de novo lipogenesis (DNL), fatty acid oxidation (FAO), lipid transport, and autophagy-lipophagy-mediated clearance, and it drives the onset and progression of MASLD. Although some drugs have been approved for patients with specific metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, therapeutic options that are broadly applicable across the full MASLD disease spectrum, particularly for patients with early steatosis, complex metabolic phenotypes, and multiple coexisting metabolic abnormalities, remain limited in terms of population coverage, long-term safety, and clearly defined therapeutic targets. In this article, relevant databases, including PubMed and the Web of Science Core Collection, were searched to include basic experimental and clinical studies related to lipid metabolism dysregulation and intervention with natural bioactive compounds within the MASLD/MASH disease spectrum, and the findings were organized according to molecular processes and clinical applications. The available evidence suggests that natural bioactive compounds may modulate hepatic lipid homeostasis by reducing fatty acid uptake and de novo lipogenesis, enhancing fatty acid oxidation, regulating lipid transport and export-related pathways, restoring autophagy-lipophagy-mediated lipid droplet clearance, and attenuating gut-liver axis dysregulation, oxidative stress, and inflammatory injury. From the perspective of lipid metabolism, this article summarizes the molecular processes, clinical evidence, and application barriers associated with natural bioactive compounds in the intervention of MASLD, with the aim of providing a basis for subsequent research on the prevention and treatment of MASLD using natural products.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: